EP3952840A4 - Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders - Google Patents

Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders Download PDF

Info

Publication number
EP3952840A4
EP3952840A4 EP19924315.5A EP19924315A EP3952840A4 EP 3952840 A4 EP3952840 A4 EP 3952840A4 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A4 EP3952840 A4 EP 3952840A4
Authority
EP
European Patent Office
Prior art keywords
behavioral
methods
pharmaceutical compositions
cognitive disorders
treating mental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19924315.5A
Other languages
German (de)
French (fr)
Other versions
EP3952840A1 (en
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Pharma Tech Inc
Original Assignee
La Pharma Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Pharma Tech Inc filed Critical La Pharma Tech Inc
Publication of EP3952840A1 publication Critical patent/EP3952840A1/en
Publication of EP3952840A4 publication Critical patent/EP3952840A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
EP19924315.5A 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders Pending EP3952840A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/027293 WO2020209872A1 (en) 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Publications (2)

Publication Number Publication Date
EP3952840A1 EP3952840A1 (en) 2022-02-16
EP3952840A4 true EP3952840A4 (en) 2022-11-23

Family

ID=72751206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19924315.5A Pending EP3952840A4 (en) 2019-04-12 2019-04-12 Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Country Status (6)

Country Link
EP (1) EP3952840A4 (en)
JP (1) JP7365426B2 (en)
CN (1) CN113939276A (en)
AU (1) AU2019445048A1 (en)
CA (1) CA3136633A1 (en)
WO (1) WO2020209872A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
EP3962488A4 (en) * 2019-04-30 2022-12-14 La Pharma Tech Inc. A method of treating mental, behavioral, cognitive disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2377557T1 (en) * 2004-11-24 2017-02-28 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
JP7198575B2 (en) 2017-07-11 2023-01-04 キョーリンリメディオ株式会社 Orally disintegrating tablet containing memantine hydrochloride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
TARIOT PIERRE N ET AL: "MEMANTINE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER DISEASE ALREADY RECEIVING DONEPEZIL. A RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 291, no. 3, 21 January 2004 (2004-01-21), pages 317 - 324, XP009075923, ISSN: 0098-7484, DOI: 10.1001/JAMA.291.3.317 *

Also Published As

Publication number Publication date
CN113939276A (en) 2022-01-14
WO2020209872A1 (en) 2020-10-15
JP2022535644A (en) 2022-08-10
CA3136633A1 (en) 2020-10-15
EP3952840A1 (en) 2022-02-16
JP7365426B2 (en) 2023-10-19
AU2019445048A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
EP3952840A4 (en) Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
EP3973586A4 (en) Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
EP3351616A4 (en) Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
EP3931189A4 (en) Azepino-indoles and other heterocycles for treating brain disorders
EP3746135A4 (en) Methods and compounds for treating disorders
EP3481402A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3934652A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3962488A4 (en) A method of treating mental, behavioral, cognitive disorders
EP3681477A4 (en) Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3906043A4 (en) Methods and compositions for the treatment of fabry disease
EP3810611A4 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3858353A4 (en) Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof
EP3492096A4 (en) Pharmaceutical composition for treating ocular diseases, containing cas9 protein and guide rna
EP3818085A4 (en) Compositions and uses thereof for treating disease or condition
EP3586872A4 (en) Pharmaceutical composition, antigen-binding molecules, treatment method, and screening method
EP3934646A4 (en) Pharmaceutical compositions for treating ocular diseases or disorders
EP4034109A4 (en) Method and composition for the treatment of disease
EP3636281A4 (en) Method for treating depression, and pharmaceutical composition
EP3570670A4 (en) Compositions and methods for treating lysosomal storage diseases and disorders
EP3943107A4 (en) Composition for preventing or treating brain and nervous system disease
EP3558281A4 (en) Treatment of mental, movement and behavioral disorders
EP4043012A4 (en) Drug for treating artery-related diseases, and use thereof
EP3946433A4 (en) Compositions, devices and methods for treating fabry disease
EP3979985A4 (en) Compositions and methods for treating central nervous system disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20221018BHEP

Ipc: A61K 47/00 20060101ALI20221018BHEP

Ipc: A61K 31/495 20060101ALI20221018BHEP

Ipc: A61K 31/55 20060101ALI20221018BHEP

Ipc: A61K 31/13 20060101ALI20221018BHEP

Ipc: A61K 9/48 20060101ALI20221018BHEP

Ipc: A61K 9/20 20060101ALI20221018BHEP

Ipc: A61K 9/14 20060101ALI20221018BHEP

Ipc: A61K 9/10 20060101ALI20221018BHEP

Ipc: A61K 9/08 20060101AFI20221018BHEP